

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Voriconazole

May 20, 2025

Therapeutic category

Antibiotic preparations acting mainly on mold

Non-proprietary name

Voriconazole

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision						
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Rifampicin, rifabutin, efavirenz, ritonavir, lopinavir/ritonavir, nirmatrelvir/ritonavir, carbamazepine, barbital, phenobarbital, pimozone, quinidine, ivabradine, ergot alkaloids (ergotamine/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, ergometrine, methylethergometrine), triazolam, ticagrelor, asunaprevir, lomitapide, blonanserin, suvorexant, rivaroxaban, <u>riociguat</u>, azelnidipine, olmesartan medoxomil/azelnidipine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], anamorelin, lurasidone, isavuconazonium, finerenone</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table border="1" data-bbox="241 1070 1111 1350"> <thead> <tr> <th data-bbox="241 1070 450 1136">Drugs</th> <th data-bbox="452 1070 790 1136">Signs, symptoms, and treatment</th> <th data-bbox="792 1070 1111 1136">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="241 1137 450 1350"><u>Riociguat</u></td> <td data-bbox="452 1137 790 1350"><u>The blood concentration of riociguat may be increased by co-administration with voriconazole.</u></td> <td data-bbox="792 1137 1111 1350"><u>Voriconazole inhibits multiple CYP isoforms (CYP1A1, CYP3A, etc.), which are the metabolizing enzyme of riociguat.</u></td> </tr> </tbody> </table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<u>Riociguat</u>	<u>The blood concentration of riociguat may be increased by co-administration with voriconazole.</u>	<u>Voriconazole inhibits multiple CYP isoforms (CYP1A1, CYP3A, etc.), which are the metabolizing enzyme of riociguat.</u>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Rifampicin, rifabutin, efavirenz, ritonavir, lopinavir/ritonavir, nirmatrelvir/ritonavir, carbamazepine, barbital, phenobarbital, pimozone, quinidine, ivabradine, ergot alkaloids (ergotamine/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, ergometrine, methylethergometrine), triazolam, ticagrelor, asunaprevir, lomitapide, blonanserin, suvorexant, rivaroxaban, azelnidipine, olmesartan medoxomil/azelnidipine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], anamorelin, lurasidone, isavuconazonium, finerenone, <u>eplerenone</u></p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.) (deleted)</p>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors					
<u>Riociguat</u>	<u>The blood concentration of riociguat may be increased by co-administration with voriconazole.</u>	<u>Voriconazole inhibits multiple CYP isoforms (CYP1A1, CYP3A, etc.), which are the metabolizing enzyme of riociguat.</u>					

(N/A)

10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)

(N/A)

Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
<u>Eplerenone</u>	<u>The blood concentration of eplerenone may be increased by co-administration with voriconazole, and the effect may be enhanced.</u>	<u>Voriconazole inhibits the metabolizing enzyme of eplerenone (CYP3A4).</u>

10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)

Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
<u>Riociguat</u>	<u>The blood concentration of riociguat may be increased by co-administration with voriconazole. When co-administration with voriconazole is necessary, patients should be monitored for their condition and dose reduction of riociguat should be considered as necessary.</u>	<u>Voriconazole inhibits the metabolizing enzyme of riociguat (CYP3A).</u>

(N/A) Not Applicable. No corresponding language is included in the current PRECAUTIONS.